These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 926982)
41. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Chan HL; Wang H; Niu J; Chim AM; Sung JJ Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024 [TBL] [Abstract][Full Text] [Related]
42. Hepatoprotective and immunomodulatory effects of antioxidant therapy. Láng I; Deák G; Nékám K; Müzes G; González-Cabello R; Gergely P; Fehér J Acta Med Hung; 1988; 45(3-4):287-95. PubMed ID: 3074277 [TBL] [Abstract][Full Text] [Related]
43. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. Gordon A; Hobbs DA; Bowden DS; Bailey MJ; Mitchell J; Francis AJ; Roberts SK J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):275-80. PubMed ID: 16460486 [TBL] [Abstract][Full Text] [Related]
44. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C]. Pár A; Róth E; Rumi G; Kovács Z; Nemes J; Mózsik G Orv Hetil; 2000 Jul; 141(30):1655-9. PubMed ID: 10962902 [TBL] [Abstract][Full Text] [Related]
45. Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens. Huber R; Futter I; Lüdtke R Eur J Med Res; 2005 Feb; 10(2):68-70. PubMed ID: 15817425 [TBL] [Abstract][Full Text] [Related]
46. [Therapy of chronic hepatitis (author's transl)]. Arnold W; Meyer zum Büschenfelde KH Leber Magen Darm; 1981 Apr; 11(2):73-80. PubMed ID: 6164895 [TBL] [Abstract][Full Text] [Related]
47. [Membrane protectors and silymarin in hepatology therapy]. Grossi F; Viola F Clin Ter; 1981 Jan; 96(1):11-23. PubMed ID: 7016408 [No Abstract] [Full Text] [Related]
48. [About a new medicamentous treatment of the varicose syndrome (author's transl)]. Berson I Schweiz Rundsch Med Prax; 1978 Jun; 67(26):981-4. PubMed ID: 353780 [No Abstract] [Full Text] [Related]
49. Short term treatment of type II hyperlipoproteinaemia with silymarin. Somogyi A; Ecsedi GG; Blázovics A; Miskolczi K; Gergely P; Fehér J Acta Med Hung; 1989; 46(4):289-95. PubMed ID: 2699920 [TBL] [Abstract][Full Text] [Related]
50. [Clinical study of the therapeutic action of silymarin in acute infectious hepatitis in childhood]. Mingrino F; Tosti U; Anania S; Buglioni MC; Viola F Minerva Pediatr; 1979 Mar; 31(6):451-6. PubMed ID: 470888 [No Abstract] [Full Text] [Related]
51. [Changes in the biochemical picture of chronic active hepatitis in the course of interrupted treatment with Legalon (author's transl)]. Hanták I; Mikulecký M; Kratochvílová H Bratisl Lek Listy; 1980 Nov; 74(5):555-68. PubMed ID: 7448591 [No Abstract] [Full Text] [Related]
56. [A novel model of experimental toxic hepatitis/acute degenerative hepatitis induced by frog virus 3 (FV3) in the mouse (author's transl)]. Elharrar M; Bingen A; Drillien R; Gendrault JL; Steffan AM; Kirn A Arzneimittelforschung; 1975 Oct; 25(10):1586-91. PubMed ID: 1081877 [TBL] [Abstract][Full Text] [Related]
57. [Letter: Silymarine against acute degenerative hepatitis in mice induced by FV 3. Experimental study of its activity]. Kirn A; Gut JP; Gendrault JL Nouv Presse Med; 1974 Sep; 3(31):1960. PubMed ID: 4374682 [No Abstract] [Full Text] [Related]
58. [Successes in novocain therapy in the control of premature ageing (author's transl)]. Zdichynec B Z Alternsforsch; 1977; 32(3):267-9. PubMed ID: 337694 [TBL] [Abstract][Full Text] [Related]
59. [What about chronic active hepatitis today? (author's transl)]. Geubel AP Acta Gastroenterol Belg; 1976; 39(9-10):318-27. PubMed ID: 1007816 [No Abstract] [Full Text] [Related]